Stockscreener 앱 받기
8.2818
6.92%
0.5318
Verastem Inc 주식(VSTM)의 최신 뉴스
Tempus partners with Verastem for companion diagnostic development - Yahoo Finance
Tempus AI teams up with Verastem for companion diagnostic test - Seeking Alpha
Tempus and Verastem partner on ovarian cancer diagnostic test - Investing.com Australia
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - BioSpace
(VSTM) Investment Analysis - news.stocktradersdaily.com
Verastem (VSTM) Plans to Offer 3.43 Million Shares of Common Sto - GuruFocus
Verastem: Q1 Earnings Snapshot - Greenwich Time
Verastem (VSTM) Advances Pipeline with Key Developments | VSTM S - GuruFocus
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates - BioSpace
Verastem Oncology Reports First Quarter 2025 Financial Results a - GuruFocus
Verastem, Inc. SEC 10-Q Report - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolent Health (EVH), Verastem (VSTM) and Sight Sciences (SGHT) - The Globe and Mail
Today's Research Reports on Stocks to Watch: Alder BioPharmaceuticals Inc. and Verastem Inc. - ACCESS Newswire
Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased - MSN
Verastem (VSTM) Sees Price Target Increase and FDA Approval Boos - GuruFocus
Verastem (VSTM) Sees Increased Price Target Following FDA Approval | VSTM Stock News - GuruFocus
High-graded low-grade ovarian duo wins for Verastem at FDA - BioWorld MedTech
B. Riley Adjusts Verastem Price Target to $13 From $12, Maintains Buy Rating - marketscreener.com
Mizuho Adjusts Price Target on Verastem to $16 From $8, Maintains Outperform Rating - marketscreener.com
Verastem (VSTM) Stock Update: Analyst Raises Price Target to $14 | VSTM Stock News - GuruFocus
RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk - marketscreener.com
Verastem (VSTM) Price Target Increased by RBC Capital Analyst | VSTM Stock News - GuruFocus
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer - BioSpace
Verastem stock price target raised to $19 by Jefferies - Investing.com Canada
Verastem Gains FDA Approval for New Cancer Treatment - TipRanks
Health Care Stocks See Mixed Results In Market Movements - Finimize
Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer - insights.citeline.com
Accelerated FDA Approval Makes Verastem Drug the First Therapy for Rare Type of Ovarian Cancer - MedCity News
FDA Approves Avutometinib/Defactinib for Adults With KRAS-Mutated Recurrent LGSOC - Pharmacy Times
US FDA approves Verastem's ovarian cancer therapy - Reuters
FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer - Benzinga
US FDA approves Verastem’s cancer therapy - WHTC
Verastem (VSTM) Gains as Analyst Increases Price Target Following FDA Approval | VSTM Stock News - GuruFocus
Verastem Oncology Cancer Drug Combination Gets FDA Approval - marketscreener.com
FDA grants Verastem first approval for rare ovarian cancer treatment - Endpoints News
Verastem Says AVMAPKI FAKZYNJA Co-Pack Expected To Be Available For Adult Patients In U.S. In One Week - marketscreener.com
FDA Greenlights Verastem's (VSTM) New Cancer Treatment - GuruFocus
Verastem's Avmapki Fakzynja receives FDA accelerated approval for ovarian cancer - Seeking Alpha
U.S. FDA approves Verastem's cancer therapy - marketscreener.com
FDA Grants Approval for Verastem's (VSTM) Cancer Treatment Combo - GuruFocus
FDA Grants Approval for Verastem's (VSTM) Cancer Treatment Combo | VSTM Stock News - GuruFocus
Trading (VSTM) With Integrated Risk Controls - news.stocktradersdaily.com
Invesco Ltd. Grows Holdings in Verastem, Inc. (NASDAQ:VSTM) - Defense World
B. Riley Issues Pessimistic Outlook for Verastem Earnings - Defense World
Verastem (VSTM) Schedules Conference Call with Key Executives | - GuruFocus
Verastem Oncology to Present at Upcoming Investor Conferences | - GuruFocus
Ovarian Cancer Market: Epidemiology, Therapies, Companies, - openPR.com
1.16%
2.33%
자본화:
|
볼륨(24시간):